These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38973234)

  • 21. Somatic Features of Response and Relapse in Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin Immunotherapy.
    Bacon JVW; Müller DC; Ritch E; Annala M; Dugas SG; Herberts C; Vandekerkhove G; Seifert H; Zellweger T; Black PC; Bubendorf L; Wyatt AW; Rentsch CA
    Eur Urol Oncol; 2022 Dec; 5(6):677-686. PubMed ID: 34895867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic Immune-inflammation Index (SII) During Induction has Higher Predictive Value Than Preoperative SII in Non-muscle-invasive Bladder Cancer Patients Receiving Intravesical Bacillus Calmette -Guerin.
    Deng-Xiong L; Qing-Xin Y; De-Chao F; Fa-Cai Z; Rui-Cheng W; Shi X; Han P
    Clin Genitourin Cancer; 2023 Jun; 21(3):e145-e152. PubMed ID: 36503724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Multi-Gene Signature of Non-Muscle-Invasive Bladder Cancer Identifies Patients Who Respond to Immunotherapies Including Bacillus Calmette-Guérin and Immune Checkpoint Inhibitors.
    Baek SW; Leem SH
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer.
    McElree IM; Steinberg RL; Mott SL; O'Donnell MA; Packiam VT
    JAMA Netw Open; 2023 Feb; 6(2):e230849. PubMed ID: 36853609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Intravesical instillation of bacillus Calmette-Guerin for non-muscle invasive bladder cancer: outcomes of 421 patients in a single center].
    Cai T; Lu J; Lin Z; Lup M; Liang H; Qin Z; Ye Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2023 Mar; 43(3):488-494. PubMed ID: 37087596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patients with Non-Muscle-Invasive Bladder Cancer Previously Treated with Nephroureterectomy Have a High Risk of Recurrence after Bacillus Calmette-Guérin Intravesical Instillation Therapy.
    Maeyama R; Ikeda M; Shimura S; Amano N; Murakami Y; Yamada Y; Koguchi D; Tachibana T; Kawamura M; Sakata Y; Hagiwara M; Matsumoto K; Iwamura M
    Chemotherapy; 2023; 68(4):190-196. PubMed ID: 35390791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
    Shepherd AR; Shepherd E; Brook NR
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment patterns and prognosis in patients with Bacillus Calmette-Guérin-exposed high-risk non-muscle invasive bladder cancer: a real-world data analysis.
    Nishimura N; Miyake M; Iida K; Miyamoto T; Tomida R; Numakura K; Inokuchi J; Yoneyama T; Okajima E; Yajima S; Masuda H; Terada N; Taoka R; Kobayashi T; Kojima T; Matsui Y; Nishiyama N; Kitamura H; Nishiyama H; Fujimoto K
    World J Urol; 2024 Mar; 42(1):185. PubMed ID: 38512511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer.
    Roumiguié M; Kamat AM; Bivalacqua TJ; Lerner SP; Kassouf W; Böhle A; Brausi M; Buckley R; Persad R; Colombel M; Lamm D; Palou-Redorta J; Soloway M; Brothers K; Steinberg G; Lotan Y; Sylvester R; Alfred Witjes J; Black PC
    Eur Urol; 2022 Jul; 82(1):34-46. PubMed ID: 34955291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bacillus Calmette-Guerin (BCG) therapy is safe and effective in non-muscle invasive bladder cancer (NMIBC) patients with immunomodulating conditions.
    Durant AM; Choudry MM; Madura G; Mi L; Faraj KS; Tyson MD
    Urol Oncol; 2024 Jan; 42(1):21.e21-21.e28. PubMed ID: 37852817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder Cancer.
    Inman BA; Hahn NM; Stratton K; Kopp R; Sankin A; Skinner E; Pohar K; Gartrell BA; Pham S; Rishipathak D; Mariathasan S; Davarpanah N; Carter C; Steinberg GD
    Eur Urol Oncol; 2023 Jun; 6(3):313-320. PubMed ID: 36803840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
    Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
    J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recurrence Rate and Cost Consequence of the Shortage of Bacillus Calmette-Guérin Connaught Strain for Bladder Cancer Patients.
    Ourfali S; Ohannessian R; Fassi-Fehri H; Pages A; Badet L; Colombel M
    Eur Urol Focus; 2021 Jan; 7(1):111-116. PubMed ID: 31005491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of BCG for non-muscle invasive bladder cancer following nephroureterectomy for upper tract urothelial carcinoma.
    Massari M; O'Malley P; Benidir T; Su LM; Gao H; Crispen PL
    Urol Oncol; 2024 Sep; 42(9):289.e7-289.e12. PubMed ID: 38802293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality of Life in the Phase 2/3 Trial of N-803 Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin‒Unresponsive Nonmuscle-Invasive Bladder Cancer.
    Chamie K; Chang SS; Kramolowsky EV; Gonzalgo ML; Huang M; Bhar P; Spilman P; Sender L; Reddy SK; Soon-Shiong P
    Urol Pract; 2024 Mar; 11(2):367-375. PubMed ID: 38226931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective descriptive 1-year study in France of all BCG therapy dispensations for non-muscle-invasive bladder cancer.
    Neuzillet Y; Leon P; Seisen T; Allory Y; Audenet F; Loriot Y; Masson-Lecomte A; Mejean A; Pradère B; Roumiguié M; Traxer O; Xylinas E; Fournier G; Roupret M
    BJU Int; 2023 May; 131(5):611-616. PubMed ID: 36462164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The association between BCG treatment in patients with bladder cancer and subsequent risk of developing Alzheimer and other dementia.-A Swedish nationwide cohort study from 1997 to 2019.
    Wang E; Hagberg O; Malmström PU
    PLoS One; 2023; 18(12):e0292174. PubMed ID: 38096211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.
    Sfakianos JP; Kim PH; Hakimi AA; Herr HW
    J Urol; 2014 Feb; 191(2):341-5. PubMed ID: 23973518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer.
    Zazzara M; Nazaraj A; Scarcia M; Cardo G; Carando R; Ludovico GM
    Urol Int; 2023; 107(1):64-71. PubMed ID: 34933307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.